



**HAL**  
open science

## **Oncolytic immunotherapy: The new clinical outbreak.**

Jean-François Fonteneau, Carole Achard, Cécile Zaupa, Johann Foloppe,  
Philippe Erbs

► **To cite this version:**

Jean-François Fonteneau, Carole Achard, Cécile Zaupa, Johann Foloppe, Philippe Erbs. Oncolytic immunotherapy: The new clinical outbreak.. *OncoImmunology*, 2015, 5 (1), pp.e1066961. 10.1080/2162402X.2015.1066961 . inserm-01285132v1


**HAL Id: inserm-01285132**

**<https://inserm.hal.science/inserm-01285132v1>**

Submitted on 8 Mar 2016 (v1), last revised 16 Mar 2023 (v2)

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## Oncolmmunology

Publication details, including instructions for authors and subscription information:  
<http://www.tandfonline.com/loi/koni20>

### Oncolytic immunotherapy: the new clinical outbreak

Jean-François Fonteneau<sup>a</sup>, Carole Achard<sup>a</sup>, Cécile Zaupa<sup>b</sup>, Johann Follope<sup>b</sup> & Philippe Erbs<sup>b</sup>

<sup>a</sup> INSERM UMR892, CNRS UMR6299, Université de Nantes, 44007 Nantes.

<sup>b</sup> TRANSGENE SA, 67400 Illkirch-Graffenstaden.

Accepted author version posted online: 12 Aug 2015.



[Click for updates](#)

To cite this article: Jean-François Fonteneau, Carole Achard, Cécile Zaupa, Johann Follope & Philippe Erbs (2015): Oncolytic immunotherapy: the new clinical outbreak, *Oncolmmunology*, DOI: [10.1080/2162402X.2015.1066961](https://doi.org/10.1080/2162402X.2015.1066961)

To link to this article: <http://dx.doi.org/10.1080/2162402X.2015.1066961>

Disclaimer: This is a version of an unedited manuscript that has been accepted for publication. As a service to authors and researchers we are providing this version of the accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proof will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to this version also.

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

## **Oncolytic immunotherapy: the new clinical outbreak**

Jean-François Fonteneau<sup>1</sup>, Carole Achard<sup>1</sup>, Cécile Zaupa<sup>2</sup>, Johann Foloppe<sup>2</sup>, and Philippe Erbs<sup>2</sup>.

1. INSERM UMR892, CNRS UMR6299, Université de Nantes, 44007 Nantes.
2. TRANSGENE SA, 67400 Illkirch-Graffenstaden.

Corresponding author: JF Fonteneau, INSERM UMR892, CNRS UMR6299, Institut de Recherche Thérapeutique de l'Université de Nantes, 8 quai Moncousu, BP70721, 44007 Nantes Cedex1, France.  
E-mail: jean-francois.fonteneau@inserm.fr

Accepted Manuscript

This last year was productive for the oncolytic viruses (OV) field with numerous advancements. The 9th international conference on oncolytic virus therapeutics, that has been held in Boston, USA, from the 13th to the 16th of June 2015, was the opportunity to discuss these progresses (OVC Boston 2015: the conference program with abstracts and the list of participants is available at this address: <http://ovcboston.com/final-program/>). It was locally organized by Nino Chiocca from Brigham and Women's Hospital and Samuel Rabkin from Massachusetts General Hospital. OV are viruses that infect preferentially or exclusively cancer cells and cause immunogenic cell death which induces or stimulates an anti-tumor immune response in patients <sup>1, 2</sup>. During this congress, many encouraging clinical results were presented.

T-vec from Amgen Inc. is a strain of Herpes simplex type I virus that was selected to infect tumor cells. It is modified to encode the granulocyte-macrophage colony-stimulating factor (GM-CSF) to stimulate immunity and is deleted for two virulence factors, ICP47 and ICP34.5. Results of a phase III clinical trial where T-vec was used to treat metastatic melanoma patients were recently published in the *Journal of Clinical Oncology* <sup>3</sup>. At the end of May 2015, the positive clinical benefits observed in this study led a panel of experts of the food and drugs administration (FDA) to vote for the use of T-vec in the treatment of metastatic melanoma with a large majority (22 against 1). T-vec may be soon the first FDA approved oncolytic virus.

These last years, immunotherapy of cancer has been improved by the use of checkpoint inhibitors (CPI) that are targeted therapies directed against molecules such as CTLA-4 or PD1 that inhibit the tumor cell recognition and lysis by cytotoxic T cells <sup>4</sup>. At the conference, Robert Andtbacka presented preliminary results of a phase I clinical trial where T-vec is associated with ipilimumab, a CPI targeting CTLA-4, in the treatment of metastatic melanoma. Clinical responses are better than that would be expected from the individual treatments. A Phase II comparing ipilimumab plus T-vec with ipilimumab alone is started.

Attenuated strain of measles viruses (MV) are also promising OV <sup>5</sup>. MV infects and kills tumor cells that express the entry receptor CD46 and that are deficient in the antiviral type I IFN response. The use of Edmonston strain of MV is evaluated for the treatment of several malignancies at the Mayo Clinic in Rochester, USA, by the teams of Eva Galanis and Stephen Russell. Eva Galanis presented results of phase I clinical trials for the treatment of ovarian cancer using either MV encoding the sodium/iodide symporter (MV-NIS) or the carcinoembryonic antigen (MV-CEA) <sup>6</sup>. MV-NIS or MV-CEA were injected repeatedly in the peritoneal cavity of MV-seropositive patients. Replication of MV-NIS is followed by <sup>123</sup>I SPECT/CT imaging after <sup>123</sup>I injection. Replication of MV-CEA is monitored by RT-PCR against CEA on peritoneal fluid samples. Replication of both viruses was observed after injections. Median overall survival of patients receiving low doses of MV-CEA was 10.6 months compared to 29.3 months for those receiving high doses of MV-CEA or MV-NIS. Furthermore, in this study, an induction of a T cell response against tumor antigens was observed after treatment. A phase II is now started comparing MV-NIS to chemotherapy.

Stephen Russell presented an update of the phase I clinical trial for the treatment of MV-seronegative patients with metastatic multiple myeloma. The patient he described in its paper of May 2014 <sup>7</sup>, who was alive 6 months after the treatment, is still alive today, 24 months after treatment. Stephen Russell also discussed the use of a vesicular stomatitis virus (VSV) encoding IFN- $\beta$ .

Hardev Pandha provided an update on the clinical phase I/II of CAVATAK CVA21, an oncolytic coxsackievirus, positive-sense single-stranded RNA picornavirus that binds to the N-terminal domain of ICAM-1, which is highly expressed on many solid tumors <sup>8</sup>. This phase I/II study is investigating the tolerance of multiple escalating intravenous doses of CVA21 in advanced cancer patients. To date, multiple CVA21 infusions have been generally well tolerated, and preliminary data indicate possible viral replication within tumor. Gough Au presented significant anti-tumor activity mediated by the combination of CVA21 and CPI (anti-PD1 and anti-CTLA4) in the murine B16 melanoma model and clinical evaluation of CVA21 in combination with anti-CTLA4 in advanced melanoma patients is currently underway.

Preclinical results suggest that combination of PD-1 inhibition therapy with Reolysin, that is an oncolytic reovirus evaluated in ongoing Phase III clinical trial <sup>9</sup>, confers significant survival benefit in a subcutaneous B16 melanoma model, by augmenting tumor-specific NK responses and specifically attenuating tumor-specific immunosuppression.

JX594 is a strain of vaccinia poxvirus modified by addition of the GM-CSF gene and deletion of the thymidine kinase gene. The replication of this virus requires a thymidine kinase activity that can be found in tumor cells. A phase III clinical trial for the treatment of hepatocellular carcinoma with JX594 is planned by SillaJen Biotherapeutics and Transgene SA after the encouraging clinical results of the phase II <sup>10</sup>.

Other encouraging clinical results, notably for the treatment of glioblastoma with different OV, were presented at the conference during two sessions dedicated to clinical trials. OV Basic research was also addressed such as the role of the tumor microenvironment on OV efficiency presented by John Bell <sup>11</sup>, and the role of the STING pathway in tumor development and the sensitivity of tumor cells to DNA OV presented by Glen Barber <sup>12</sup>. It is not our goal to list all advancements in the OV field that were presented at this conference. We therefore apologize to the authors of all the other studies presented at the conference that are not reviewed here.

To conclude, it is worth noting that all preclinical and clinical studies of combination of OV with CPI (anti-CTLA4, anti-PDL1 and anti-PD1) show a synergy of these two types of treatment. Thus a consensus emerges to claim that OV are good CPI allies. Indeed, OV induce or increase the lymphocytic infiltrates in tumors and CPI treatment improves their cytotoxic activity. It was therefore proposed that, whenever possible, OV would be associated with CPI in clinical trials. Finally, it was also suggested that "oncolytic virotherapy" is renamed "oncolytic immunotherapy", given the importance of the induction/stimulation of an anti-tumor immune response in the OV efficacy.

A new outbreak of good news for the OV field is now expected in Vancouver, Canada, in 2016 for the 10th international conference on oncolytic virus therapeutics.

#### **Acknowledgments:**

We thank for their financial support: "la Ligue Régionale Grand Ouest contre le Cancer (CSIRGO : CD16, CD22, CD44, CD49, CD72, CD79 and CD85)", "La Ligue Nationale contre le Cancer", "ARSMESO44 association", "la Fondation du Souffle et le Fonds de Dotation Recherche en Santé Respiratoire", "la Fondation pour la Recherche Médicale (FRM)", and "la Fondation ARC pour la recherche sur le cancer".

## References:

1. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, et al. Trial Watch:: Oncolytic viruses for cancer therapy. *Oncoimmunology* 2014; 3:e28694.
2. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. *Nat Biotechnol* 2012; 30:658-70.
3. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. *J Clin Oncol* 2015.
4. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science* 2015; 348:56-61.
5. Guillerme JB, Gregoire M, Tangy F, J.F. F. Antitumor virotherapy by attenuated measles virus (MV). *Biology (Basel)* 2013; 2:587-602.
6. Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. *Cancer Res* 2015; 75:22-30.
7. Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, et al. Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. *Mayo Clin Proc* 2014; 89:926-33.
8. Au GG, Lindberg AM, Barry RD, Shafren DR. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. *Int J Oncol* 2005; 26:1471-6.
9. Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW, et al. Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. *Cell Death Dis* 2013; 4:e728.
10. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. *Nat Med* 2013; 19:329-36.
11. Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. *Nat Med* 2015; 21:530-6.
12. Ahn J, Konno H, Barber GN. Diverse roles of STING-dependent signaling on the development of cancer. *Oncogene* 2015.